Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans. The TOS segment provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. Its TumorGraft Technology Platform consists of processes, physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from patients that it has preserved for implantation in mice, along with the patient data and molecular information associated with the tumors, are known as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company's TumorBank.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: OTCMKTS:CSBR
- CUSIP: N/A
- Web: https://championsoncology.com
- Market Cap: $34.04 million
- Outstanding Shares: 10,982,000
- 50 Day Moving Avg: $2.81
- 200 Day Moving Avg: $2.93
- 52 Week Range: $1.11 - $4.79
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: $15.41 million
- Price / Sales: 2.21
- Book Value: $0.04 per share
- Price / Book: 77.50
- EBIDTA: ($6,640,000.00)
- Net Margins: -39.52%
- Return on Equity: -215.50%
- Return on Assets: -72.50%
- Average Volume: 18,059 shs.
- Short Ratio: 4.3
Frequently Asked Questions for Champions Oncology (OTCMKTS:CSBR)
What is Champions Oncology's stock symbol?
Champions Oncology trades on the OTCMKTS under the ticker symbol "CSBR."
How were Champions Oncology's earnings last quarter?
Champions Oncology Inc (OTCMKTS:CSBR) released its quarterly earnings results on Thursday, July, 27th. The company reported ($0.22) EPS for the quarter. The firm had revenue of $3.72 million for the quarter. Champions Oncology had a negative net margin of 39.52% and a negative return on equity of 215.50%. View Champions Oncology's Earnings History.
When will Champions Oncology make its next earnings announcement?
Who are some of Champions Oncology's key competitors?
Some companies that are related to Champions Oncology include Eiger BioPharmaceuticals (EIGR), Navidea Biopharmaceuticals (NAVB), aTyr Pharma (LIFE), Galectin Therapeutics (GALT), ReNeuron Group Plc (RENE), Abzena PLC (ABZA), Palatin Technologies (PTN), CASI Pharmaceuticals (CASI), Infinity Pharmaceuticals (INFI), Sunesis Pharmaceuticals (SNSS), OvaScience (OVAS), Caladrius Biosciences (CLBS), Fibrocell Science (FCSC), Prima BioMed Ltd (PBMD), Aptose Biosciences (APTO), Threshold Pharmaceuticals (MTEM), Cleveland BioLabs (CBLI) and AEterna Zentaris (AEZS).
Who are Champions Oncology's key executives?
Champions Oncology's management team includes the folowing people:
- Joel Ackerman, Chairman of the Board
- Ronnie Morris M.D., President, Chief Executive Officer, Director
- David Miller CPA, Vice President - Finance
- Philip Breitfeld, Chief Strategic and Innovation Officer, Director
- David Sidransky M.D., Lead Independent Director
- Daniel N. Mendelson, Independent Director
- Abba David Poliakoff, Independent Director
- Scott R. Tobin, Independent Director
Who owns Champions Oncology stock?
Champions Oncology's stock is owned by a number of of institutional and retail investors. Top institutional investors include NEA Management Company LLC (14.23%), Vanguard Group Inc. (0.68%), GRT Capital Partners L.L.C. (0.37%) and Spark Investment Management LLC (0.37%). Company insiders that own Champions Oncology stock include Joel Ackerman and Ronnie Morris. View Institutional Ownership Trends for Champions Oncology.
Who bought Champions Oncology stock? Who is buying Champions Oncology stock?
Champions Oncology's stock was bought by a variety of institutional investors in the last quarter, including GRT Capital Partners L.L.C.. Company insiders that have bought Champions Oncology stock in the last two years include Joel Ackerman and Ronnie Morris. View Insider Buying and Selling for Champions Oncology.
How do I buy Champions Oncology stock?
Shares of Champions Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Champions Oncology's stock price today?
MarketBeat Community Rating for Champions Oncology (OTCMKTS CSBR)MarketBeat's community ratings are surveys of what our community members think about Champions Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Champions Oncology stock can currently be purchased for approximately $3.10.
Consensus Ratings for Champions Oncology (OTCMKTS:CSBR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Champions Oncology (OTCMKTS:CSBR)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Champions Oncology (OTCMKTS:CSBR)Earnings History by Quarter for Champions Oncology (OTCMKTS CSBR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/27/2017||Q4 2017||($0.22)||$3.72 million||View||N/A|
|3/16/2017||Q3 2017||($0.13)||$3.57 million||View||N/A|
|11/29/2016||Q2 2017||($0.05)||$4.46 million||View||N/A|
|3/15/2016||Q316||($0.21)||$1.80 million||$2.60 million||View||Listen|
Earnings Estimates for Champions Oncology (OTCMKTS:CSBR)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Champions Oncology (OTCMKTS:CSBR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Champions Oncology (OTCMKTS:CSBR)Insider Trades by Quarter for Champions Oncology (OTCMKTS:CSBR)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/21/2016||Ronnie Morris||President||Buy||30,000||$1.66||$49,800.00|| |
|10/19/2016||Ronnie Morris||President||Buy||10,000||$1.70||$17,000.00|| |
|10/18/2016||Joel Ackerman||CEO||Buy||2,000||$1.70||$3,400.00|| |
|10/14/2016||Joel Ackerman||CEO||Buy||7,300||$1.67||$12,191.00|| |
|10/14/2016||Ronnie Morris||President||Buy||10,305||$1.66||$17,106.30|| |
|10/13/2016||Ronnie Morris||President||Buy||29,695||$1.67||$49,590.65|| |
|10/10/2016||Ronnie Morris||President||Buy||9,537||$1.66||$15,831.42|| |
|10/7/2016||Joel Ackerman||CEO||Buy||8,202||$1.63||$13,369.26|| |
|9/23/2016||Joel Ackerman||CEO||Buy||33||$1.65||$54.45|| |
|9/21/2016||Joel Ackerman||CEO||Buy||5,000||$1.66||$8,300.00|| |
|9/20/2016||Ronnie Morris||President||Buy||3,000||$1.58||$4,740.00|| |
|3/11/2015||Michael Maurice Brown||Major Shareholder||Buy||6,250,000||$0.40||$2,500,000.00|| |
|3/20/2014||Daniel Newman Mendelson||Director||Buy||100,000||$1.08||$108,000.00|| |
|3/19/2014||Ronnie Morris||President||Buy||100,000||$1.07||$107,000.00|| |
|1/28/2013||Michael Maurice Brown||Major Shareholder||Buy||7,000,000||$0.50||$3,500,000.00|| |
|1/28/2013||Ronnie Morris||President||Buy||500,000||$0.50||$250,000.00|| |
Headline Trends for Champions Oncology (OTCMKTS:CSBR)
Latest Headlines for Champions Oncology (OTCMKTS:CSBR)
|The Addario Lung Cancer Medical Institute, Champions Oncology and Motivated Patients Announce a Research Collaboration and Launch of a Patient Driven Clinical Study in ROS1 Positive Cancer|
finance.yahoo.com - August 15 at 6:15 PM
|Champions Oncology, Inc. :CSBR-US: Earnings Analysis: Q4, 2017 By the Numbers : August 1, 2017|
finance.yahoo.com - August 1 at 6:15 PM
|Champions Oncology Inc (CSBR) Releases Quarterly Earnings Results|
www.americanbankingnews.com - July 28 at 6:19 PM
|Champions Oncology Reports 38% Revenue Growth for Fiscal Year Ended April 30, 2017|
finance.yahoo.com - July 27 at 5:50 PM
|Champions Oncology Schedules Fourth Quarter and Fiscal Year 2017 Earnings Call|
finance.yahoo.com - July 17 at 5:55 PM
|Champions Oncology Inc (CSBR) Upgraded to "Hold" at ValuEngine|
www.americanbankingnews.com - June 24 at 12:38 AM
|Champions Oncology (CSBR) Receiving Somewhat Positive News Coverage, Analysis Finds|
www.americanbankingnews.com - April 22 at 1:59 PM
|Champions Oncology (CSBR) Given Media Impact Score of 0.56|
www.americanbankingnews.com - April 18 at 10:21 AM
|CHAMPIONS ONCOLOGY, INC. Financials|
finance.yahoo.com - March 23 at 4:58 PM
|Champions Oncology (CSBR) Stock Delivers Strong Quarterly Improvement|
seekingalpha.com - March 21 at 10:44 AM
|Q3 2017 Champions Oncology Inc Earnings Release - After Market Close|
us.rd.yahoo.com - March 17 at 4:51 PM
|CHAMPIONS ONCOLOGY, INC. Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - March 17 at 4:51 PM
|Champions Oncology Reports 40% Revenue Growth|
finance.yahoo.com - March 16 at 5:54 PM
|Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 16, 2017|
finance.yahoo.com - March 7 at 12:11 PM
|Champions Oncology Announces New Collection of Patient-Derived Xenograft (PDX) Models Available for Translational Research|
finance.yahoo.com - February 16 at 12:28 PM
|Champions Oncology Retains Hayden IR to Execute Comprehensive Investor Relations Program|
finance.yahoo.com - January 19 at 3:18 PM
|Q2 2017 Champions Oncology Inc Earnings Release - After Market Close|
us.rd.yahoo.com - November 30 at 9:52 AM
|Champions Oncology Reports 50% Revenue Growth, Accelerated Progress on Path to Profitability and Future Role Changes of the Senior Leadership|
us.rd.yahoo.com - November 30 at 9:52 AM
|CHAMPIONS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Pr|
us.rd.yahoo.com - November 30 at 9:52 AM
|4:18 pm Champions Oncology (thinly traded) reports Q3 EPS $0.00 vs ($0.20) year ago on revs +51.5% y/y to $4.5 mln and reaffirms annual revenue guidance; details new strategic emphasis|
us.rd.yahoo.com - November 30 at 9:52 AM
|Champions Oncology to Announce Second Quarter Financial Results on Tuesday, November 29, 2016|
finance.yahoo.com - November 23 at 12:20 PM
|SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Delaware Law by Certain Officers and Directors of Champions Oncology, Inc.|
finance.yahoo.com - November 15 at 4:46 PM
|CHAMPIONS ONCOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - November 1 at 4:35 PM
|CHAMPIONS ONCOLOGY, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders|
biz.yahoo.com - October 14 at 4:18 PM
|8:25 am Champions Oncology reports Q1 results, reaffirms FY17 rev guidance|
finance.yahoo.com - September 9 at 9:16 AM
|Champions Oncology to Announce First Quarter Financial Results on Friday, September 9, 2016|
finance.yahoo.com - September 6 at 9:20 AM
|CHAMPIONS ONCOLOGY, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - July 29 at 1:11 PM
|Champions Oncology Announces Revenue Up 26%, Projects 43% - 60% Growth For Current Fiscal Year|
finance.yahoo.com - July 28 at 8:00 AM
|CHAMPIONS ONCOLOGY, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits|
biz.yahoo.com - May 18 at 5:15 PM
|CHAMPIONS ONCOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial State|
biz.yahoo.com - April 13 at 4:01 PM
|Champions Oncology Names Philip Breitfeld As Director|
feeds.benzinga.com - April 12 at 2:06 PM
|CHAMPIONS ONCOLOGY, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St|
biz.yahoo.com - March 25 at 3:02 PM
|Champions Oncology Reports Results for the Third Quarter Ended January 31, 2016|
finance.yahoo.com - March 15 at 8:30 AM
|Q3 2016 Champions Oncology Inc Earnings Release - Before Market Open|
biz.yahoo.com - March 15 at 7:07 AM
|Champions To Present at the 28th Annual ROTH Capital Conference on March 16, 2016|
finance.yahoo.com - March 11 at 9:00 AM
|Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2016|
finance.yahoo.com - March 10 at 10:00 AM
|CHAMPIONS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and|
biz.yahoo.com - December 14 at 4:35 PM
|Champions Oncology Leading Paradigm Shift to Incorporation of PDX Models into Clinical Trial Strategy|
finance.yahoo.com - December 14 at 4:01 PM
|Q2 2016 Champions Oncology Inc Earnings Release - After Market Close|
biz.yahoo.com - December 14 at 7:07 AM
Champions Oncology (CSBR) Chart for Friday, August, 18, 2017